Ziftomenib
MLL Rearrangement
Kura Oncology, Inc.Small moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 89/ 100
Competitive context
5 Active assets in the MLL Rearrangement cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cytosin-Arabinosid Kura Oncology, Inc. | Phase 1 | CC |
Fludarabine Kura Oncology, Inc. | Phase 1 | CC |
FILGRASTIM Kura Oncology, Inc. | Phase 1 | CC |
Idarubicine Kura Oncology, Inc. | Phase 1 | CC |
Gilteritinib Kura Oncology, Inc. | Phase 1 | CC |
Same molecule, other indications
Ziftomenib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →